Home  »  Company   »  Now Is A Good Time To Buy Maravai LifeSciences Hol...

Now Is A Good Time To Buy Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI)

During the recent session, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)’s traded shares were 0.41 million. At the last check today, the stock’s price was $24.88, reflecting an intraday loss of -5.35% or -$1.4. The 52-week high for the MRVI share is $63.55, that puts it down -155.43 from that peak though still a striking 7.36% gain since the share price plummeted to a 52-week low of $23.05. The company’s market capitalization is $6.54B, and the average intraday trading volume over the past 10 days was 1.49 million shares, and the average trade volume was 1.35 million shares over the past three months.

Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) trade information

Maravai LifeSciences Holdings Inc. (MRVI) registered a -5.35% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -5.35% in intraday trading to $24.88 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 2.18%, and it has moved by -10.92% in 30 days. Based on these gigs, the overall price performance for the year is -49.42%. The short interest in Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) is 6.0 million shares and it means that shorts have 4.94 day(s) to cover.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Maravai LifeSciences Holdings Inc. (MRVI) estimates and forecasts

Statistics show that Maravai LifeSciences Holdings Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Maravai LifeSciences Holdings Inc. (MRVI) shares have gone down -14.09% during the last six months, with a year-to-date growth rate more than the industry average at 15.00% against 5.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 2.30% this quarter and then drop -2.30% in the quarter after that. In the rating firms’ projections, revenue will increase 17.00% compared to the previous financial year.

Revenue for the current quarter is expected to be $233.24 million as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $229.29 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $217.78 million and $204.81 million respectively. In this case, analysts expect current quarter sales to grow by 7.10% and then jump by 12.00% in the coming quarter.

While earnings are projected to return 422.90% in 2022, the next five years will return -1.40% per annum.

MRVI Dividends

Maravai LifeSciences Holdings Inc. is due to release its next quarterly earnings on August 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)’s Major holders

Maravai LifeSciences Holdings Inc. insiders own 0.21% of total outstanding shares while institutional holders control 103.17%, with the float percentage being 103.39%. GTCR, LLC is the largest shareholder of the company, while 352 institutions own stock in it. As of Jun 29, 2022, the company held over 21.68 million shares (or 16.48% of all shares), a total value of $553.3 million in shares.

The next largest institutional holding, with 19.1 million shares, is of Select Equity Group, Inc.’s that is approximately 14.52% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $487.43 million.

Also, the Mutual Funds coming in first place with the largest holdings of Maravai LifeSciences Holdings Inc. (MRVI) shares are MFS Mid Cap Growth Fund and Vanguard Total Stock Market Index Fund. Data provided on May 30, 2022 indicates that MFS Mid Cap Growth Fund owns about 3.26 million shares. This amounts to just over 2.48 percent of the company’s overall shares, with a $83.24 million market value. The same data shows that the other fund manager holds slightly less at 3.25 million, or about 2.47% of the stock, which is worth about $82.95 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts